Overview
Enzene Inc. / Enzene Biosciences is a forward-looking global CDMO (Contract Development and Manufacturing Organization) specializing in biologics, providing integrated services from discovery, development, and scale-up to commercial supply. Central to its innovation is its patented EnzeneX™ platform—Fully-Connected Continuous Manufacturing (FCCM™)—which has been validated for commercial biologics production. This advanced platform leverages intensified perfusion (e.g. ATF systems), automated multi-column chromatography, and real-time monitoring to achieve continuous processing, increasing productivity and yield while lowering costs.
Enzene’s facilities in Pune, 60, are EU-GMP certified for both drug substance (microbial/mammalian) and drug product fill-finish operations. These sites include multiple manufacturing suites spanning capacities from ~20L to 2000L, supporting both conventional fed-batch and continuous bioprocess workflows, and offering automated fill/finish for vials, prefilled syringes, and cartridges.
BioProcess International
Looking ahead, Enzene is expanding its footprint with a new facility in Hopewell, New Jersey, designed to bring EnzeneX™ capability into the US market. The company has set ambitious targets: to reduce monoclonal antibody production costs to below US$40 per gram by 2025, while serving a wide variety of modalities and ensuring high quality, scalable, and sustainable biologics manufacturing. Enzene is also notable for its continuous improvement in downstream / upstream efficiency, regulatory compliance, and adoption of digital, analytic technologies to support process control and quality assurance.
